Torthaí cuardaigh - Andrea Pirzkall

  • 1 - 17 toradh as 17 á dtaispeáint
Beachtaigh na torthaí
  1. 1
    Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients

    Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients de réir Xiaojuan Li, Ying Lü, Andrea Pirzkall, Tracy R. McKnight, Sarah J. Nelson

    Foilsithe / Cruthaithe 2002
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy

    Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy de réir Suja Saraswathy, Forrest W. Crawford, Kathleen R. Lamborn, Andrea Pirzkall, Susan M. Chang, Soonmee Cha, Sarah J. Nelson

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Patterns of Recurrence Analysis in Newly Diagnosed Glioblastoma Multiforme After Three-Dimensional Conformal Radiation Therapy With Respect to Pre–Radiation Therapy Magnetic Resonance Spectroscopic Findings

    Patterns of Recurrence Analysis in Newly Diagnosed Glioblastoma Multiforme After Three-Dimensional Conformal Radiation Therapy With Respect to Pre–Radiation Therapy Magnetic Resona... de réir Ilwoo Park, Gregory Tamai, Michael Lee, Cynthia Chuang, Susan M. Chang, Mitchel S. Berger, Sarah J. Nelson, Andrea Pirzkall

    Foilsithe / Cruthaithe 2007
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume

    Survival analysis in patients with glioblastoma multiforme: Predictive value of choline‐to‐n‐acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volu... de réir Joonmi Oh, Roland G. Henry, Andrea Pirzkall, Ying Lü, Xiaojuan Li, I. Catalaa, Susan M. Chang, William P. Dillon, Sarah J. Nelson

    Foilsithe / Cruthaithe 2004
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM

    Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM de réir Forrest W. Crawford, Inas S. Khayal, Colleen McGue, Suja Saraswathy, Andrea Pirzkall, Soonmee Cha, Kathleen R. Lamborn, Susan M. Chang, Mitchel S. Berger, Sarah J. Nelson

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma

    Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma de réir Andrea Pirzkall, Colleen McGue, Suja Saraswathy, Soonmee Cha, Raymond Liu, Scott R. VandenBerg, Kathleen R. Lamborn, Mitchel S. Berger, Susan M. Chang, Sarah J. Nelson

    Foilsithe / Cruthaithe 2009
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Molecular Biomarker Analyses Using Circulating Tumor Cells

    Molecular Biomarker Analyses Using Circulating Tumor Cells de réir Elizabeth A. Punnoose, Siminder Atwal, Jill M. Spoerke, Heidi Savage, Ajay Pandita, Ru‐Fang Yeh, Andrea Pirzkall, Bernard M. Fine, Lukas C. Amler, Daniel S. Chen, Mark R. Lackner

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib

    Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib de réir Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine

    Foilsithe / Cruthaithe 2011
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib

    Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Er... de réir Elizabeth A. Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M. Fine, Brett Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, Mark R. Lackner

    Foilsithe / Cruthaithe 2012
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5‐fluorouracil or carboplatin/paclitaxel for first‐line treatment of recurrent/metastatic squamous cell carcinoma of the... de réir Antonio Jimeno, Jean‐Pascal Machiels, Lori J. Wirth, Pol Specenier, Tanguy Y. Seiwert, F. Mardjuadi, Xiaodong Wang, Amy V. Kapp, S. Royer-Joo, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Paul Clement

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors

    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors de réir Dejan Juric, Rodrigo Dienstmann, Andrés Cervantes, Manuel Hidalgo, Wells A. Messersmith, George R. Blumenschein, Josep Tabernero, Desamparados Roda, Antonio Calles, Antonio Jimeno, Xiaodong Wang, Sandra Sanabria Bohórquez, Cecilia Leddy, Catherine Littman, Amy V. Kapp, David S. Shames, Elicia Penuel, Lukas C. Amler, Andrea Pirzkall, José Baselga

    Foilsithe / Cruthaithe 2015
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck

    High Heregulin Expression Is Associated with Activated HER3 and May Define an Actionable Biomarker in Patients with Squamous Cell Carcinomas of the Head and Neck de réir David S. Shames, Juliet G. Carbon, Walter Kim, Adrian M. Jubb, Cleopatra Kozlowski, Tom Januario, An Do, Ling Fu, Yuanyuan Xiao, Rajiv Raja, Brittany Jiang, Ashi Malekafzali, Howard M. Stern, Jeff Settleman, Timothy R. Wilson, Garret M. Hampton, Robert L. Yauch, Andrea Pirzkall, Lukas C. Amler

    Foilsithe / Cruthaithe 2013
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter

    Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter de réir Xueping Qu, Thomas Sandmann, Henry F. Frierson, Lingfeng Fu, Eloisa Fuentes, Kimberly Walter, Kwame Okrah, Craig A. Rumpel, Christopher A. Moskaluk, Shi‐Long Lu, Yulei Wang, Richard Bourgon, Elicia Penuel, Andrea Pirzkall, Lukas C. Amler, Mark R. Lackner, Josep Tabernero, Garret M. Hampton, Omar Kabbarah

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

    Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study) de réir Jérôme Fayette, Lori J. Wirth, Cristina Oprean, Anghel Adrian Udrea, Antonio Jimeno, Danny Rischin, Christopher M. Nutting, Paul M. Harari, Tibor Csőszi, Dana Cernea, Paul E. O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan B. Vermorken

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

    Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal Canc... de réir Andrew G. Hill, Michael Findlay, Matthew Burge, Christopher Jackson, Pilar Alfonso, Leslie Samuel, Vinod Ganju, Meinolf Karthaus, Alessio Amatu, Mark Jeffery, Maria Di Bartolomeo, John Bridgewater, Andrew L. Coveler, Manuel Hidalgo, Amy V. Kapp, Roxana I. Sufan, Bruce McCall, William D. Hanley, Elicia Penuel, Andrea Pirzkall, Josep Tabernero

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

    Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors de réir Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene P. Kennedy, Mario R. Mautino, Charles J. Link, Ray Lin, Stephanie Royer‐Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

    Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors de réir Kyung Hae Jung, Patricia LoRusso, Howard A. Burris, Michael A. Gordon, Yung‐Jue Bang, Matthew D. Hellmann, Andrés Cervantes, María Ochoa de Olza, Aurélien Marabelle, F. Stephen Hodi, Myung‐Ju Ahn, Leisha A. Emens, Fabrice Barlési, Omid Hamid, Emiliano Calvo, David F. McDermott, Hatem Soliman, Ina Rhee, Ray Lin, Tony Pourmohamad, Julia Suchomel, Amy Lew Tsuhako, Kari M. Morrissey, Sami Mahrus, Roland Morley, Andrea Pirzkall, S. Lindsey Davis

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: